Skip to main content
REGN
NASDAQ Life Sciences

FDA Approves Regeneron's Pasatru, First Drug to Reduce New Bone Lesions in FOP

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$840.505
Mkt Cap
$86.534B
52W Low
$541
52W High
$843.258
52W Position info
55% above low
Off High info
at 52W high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

REGN sits 55% above its 52-week low of $541.

Summary

Regeneron won FDA approval for Pasatru (garetosmab-grts), the first and only treatment shown to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). The approval is based on the Phase 3 OPTIMA trial, where Pasatru cut new HO lesions by 90% and 94% at the two doses versus placebo, and reduced clinician-assessed flare-ups by 88% and 15%. FOP is an ultra-rare disease affecting roughly 900 people worldwide, but this approval validates Regeneron's Activin A discovery and adds a new commercial product to its rare disease portfolio. The company plans a pediatric trial (OPTIMA 2) later this year and has regulatory submissions under review in the EU and planned in Japan. This is a meaningful pipeline-to-market event for a large-cap biotech, though the ultra-rare patient population limits near-term revenue impact.

At the time of this announcement, REGN was trading at $840.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.5B. The 52-week trading range was $541.00 to $843.26. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

REGN - Latest Insights

REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $950.03 info
Change: +$50.03 (+6%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 12:34 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $910.52
Real-time Price: $950.03 info
Change: +$39.51 (+4%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $856.00
Real-time Price: $950.03 info
Change: +$94.03 (+11%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $950.03 info
Change: +$115.03 (+14%) info
Market Cap: $98.825B info
REGN
Oct 12, 2026, 12:06 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $764.45
Real-time Price: $950.03 info
Change: +$185.58 (+24%) info
Market Cap: $98.825B info